Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Glucagonlike peptide 1 analogs in diabetes care

Adrienne J. Lindblad, Scott Garrison and G. Michael Allan
Canadian Family Physician May 2017, 63 (5) 371;
Adrienne J. Lindblad
Knowledge Translation and Evidence Coordinator with the Alberta College of Family Physicians in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Garrison
Associate Professor in the Department of Family Medicine at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Michael Allan
Professor and Director of Evidence-Based Medicine in the Department of Family Medicine at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Do glucagonlike peptide 1 (GLP1) analogs improve patient outcomes in type 2 diabetes?

Bottom line

Compared with placebo, semaglutide and liraglutide, but not lixisenatide, reduce cardiovascular disease (CVD) for about 1 in 50 patients with diabetes with existing CVD over 2 to 4 years, irrespective of specific hemoglobin A1c (HbA1c) targets. They reduce weight, but about 1 in 25 more patients than in the placebo group stopped treatment owing to gastrointestinal effects. Some uncertainty around neoplasm risk remains.

Evidence

Evidence from 3 RCTs (mean age 60 to 65, diabetes for 9 to 14 years, > 80% had past CVD, all GLP1 analogs given subcutaneously vs placebo) was statistically significant.

  • An RCT of liraglutide (1.8 mg/d) followed 9340 patients for 3.8 years1:

    • -Initial HbA1c level of 8.7% decreased to about 7.7% for liraglutide versus 8.1% for placebo.

    • -Rate of CVD was 13% versus 14.9% (number needed to treat [NNT] = 53); NNT = 72 for mortality; and harms included gallbladder disease (number needed to harm [NNH] = 83).

  • An RCT of semaglutide (0.5 or 1 mg/wk; pooled data) followed 3297 patients for 2.1 years2:

    • -Initial HbA1c level of 8.7% decreased to 7.3% to 7.6% for semaglutide versus 8.3% for placebo.

    • -Rate of CVD was 6.6% versus 8.9% (NNT = 44); no difference in mortality; and harms were retinopathy (NNH = 83).

  • An RCT of lixisenatide (20 µg/d) followed 6068 patients for 2.1 years3:

    • -Initial HbA1c level of 7.6% decreased to about 7.3% for lixisenatide versus about 7.6% for placebo.

    • -No difference in CVD or mortality.

  • Other findings were weight loss (0.7 to 4.3 kg) and reduced nephropathy (NNT = 67 to 98; not with lixisenatide). Hypoglycemia was no different or slightly lower.

    • -Patients often discontinued treatment owing to gastrointestinal irritation (NNH = 16 to 33).

  • Neoplasms were numerically higher with GLP1 use.1–3

    • -Some meta-analyses found no cancer risk.4,5 When only the highest-quality liraglutide RCTs were analyzed, the risk increased (odds ratio = 2.60, 95% CI 1.08 to 6.27).5

    • -Safety might not have been properly evaluated.6

    • -A 2014 review did not reach a “final conclusion” on causality between incretins and pancreatic cancer, despite stating concerns were not consistent with evidence.7

Context

  • Clinicians should prioritize patient-oriented outcomes (eg, CVD) rather than glucose levels or microalbuminuria.

  • Large RCTs of dipeptidyl peptidase 4 inhibitors demonstrate no effect on CVD and minimal to no effect on microvascular outcomes.8

  • Liraglutide is the only GLP1 analog available in Canada with evidence from a large CVD trial. It costs about $185 per month; it is often covered by private insurance, but it is not covered by public insurance outside of Quebec.

Implementation

Liraglutide and semaglutide (but not lixisenatide)1–3 join empagliflozin9 as second-line glucose-lowering agents with evidence of modest CVD risk reduction. Of note, these trials enrolled patients with very high CVD risk. The NNT in lower-risk diabetes patients would be less impressive. When additional glucose lowering is desired, it is reasonable to add liraglutide or semaglutide to metformin when the higher cost, need for injection, and potential for nausea do not dissuade the patient. Weight loss is modest, but variable and not sustained on discontinuation.10

Notes

Tools for Practice

Tools for Practice articles in Canadian Family Physician (CFP) are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in CFP are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • Competing interests

    None declared

  • The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Marso SP,
    2. Daniels GH,
    3. Brown-Frandsen K,
    4. Kristensen P,
    5. Mann JF,
    6. Nauck MA,
    7. et al
    . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375(4):311-22.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Marso SP,
    2. Bain SC,
    3. Consoli A,
    4. Eliaschewitz FG,
    5. Jódar E,
    6. Leiter LA,
    7. et al
    . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375(19):1834-44.
    OpenUrlPubMed
  3. 3.↵
    1. Pfeffer MA,
    2. Claggett B,
    3. Diaz R,
    4. Dickstein K,
    5. Gerstein HC,
    6. Køber LV,
    7. et al
    . Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373(23):2247-57.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Chen H,
    2. Zhou X,
    3. Chen T,
    4. Liu B,
    5. Jin W,
    6. Gu H,
    7. et al
    . Incretin-based therapy and risk of pancreatic cancer in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Ther 2016;7(4):725-42.
    OpenUrl
  5. 5.↵
    1. Alves C,
    2. Batel-Marques F,
    3. Macedo AF
    . A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012;98(2):271-84.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Cohen D
    . Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Egan AG,
    2. Blind E,
    3. Dunder K,
    4. de Graeff PA,
    5. Hummer BT,
    6. Bourcier T,
    7. et al
    . Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med 2014;370(9):794-7. Erratum in: N Engl J Med 2014;370(23):2253.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Barry A,
    2. Allan GM
    . DPP-4 inhibitors: protecting your sweet heart? Edmonton, AB: Tools for Practice; 2015.
  9. 9.↵
    1. Zinman B,
    2. Wanner C,
    3. Lachin JM,
    4. Fitchett D,
    5. Bluhmki E,
    6. Hantel S,
    7. et al
    . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373(22):2117-28.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Antony N,
    2. Korownyk C
    . Liraglutide: weighing the evidence for weight loss? Edmonton, AB: Tools for Practice; 2016.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 63 (5)
Canadian Family Physician
Vol. 63, Issue 5
1 May 2017
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Glucagonlike peptide 1 analogs in diabetes care
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Glucagonlike peptide 1 analogs in diabetes care
Adrienne J. Lindblad, Scott Garrison, G. Michael Allan
Canadian Family Physician May 2017, 63 (5) 371;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Glucagonlike peptide 1 analogs in diabetes care
Adrienne J. Lindblad, Scott Garrison, G. Michael Allan
Canadian Family Physician May 2017, 63 (5) 371;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Tools for Practice

  • Virtual versus in-person primary care visits
  • Exercise-induced osteoarthritis
  • Is 45 the new 50 in colorectal cancer screening?
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2021 by The College of Family Physicians of Canada

Powered by HighWire